Launching today, the PNOC Foundation announced the Lose No Child campaign, a $50 million campaign to accelerate progress against pediatric brain cancer, the leading cause of cancer death in children and young adults.

The campaign seeks to achieve in just five years what typically takes a decade—bringing safer, more effective treatments to children worldwide.

On August 6, 2025, the Food and Drug Administration granted accelerated approval to dordaviprone (Modeyso, Jazz Pharmaceuticals, Inc.), a protease activator, for adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy.

Launching today, the PNOC Foundation announced the Lose No Child campaign, a $50 million campaign to accelerate progress against pediatric brain cancer, the leading cause of cancer death in children and young adults.

The campaign seeks to achieve in just five years what typically takes a decade—bringing safer, more effective treatments to children worldwide.

On August 6, 2025, the Food and Drug Administration granted accelerated approval to dordaviprone (Modeyso, Jazz Pharmaceuticals, Inc.), a protease activator, for adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy.